Golden
Aegle Therapeutics

Aegle Therapeutics

Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles ("EVs") from allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”).

Aegle Therapeutics has proprietary technology for extracellular vesicle isolation. The U.S. Food and Drug Administration (FDA) cleared the company's first Investigational New Drug (IND) application to begin clinical trials in burn patients in 2018.The Phase 1/2a study includes severe second degree burn patients and will evaluate the safety of extracellular vesicle therapy and is an open label dose escalation protocol in patients at several sites in the United States.



Aegle's extracellular vesicles isolated from MSCs, called AGLE-102, are claimed to have potential to enhance healing, reduce scarring, minimize contraction and improve overall cosmesisfor patients with burns who suffer scarring, disfigurement, loss of mobility and chronic pain.

Funding

Seed

On May 1, 2018 Aegle Therapeutics completed their seed funding round with and undisclosed amount of funding from Ocean Azul Partners. 

Timeline

May 1, 2018

Seed funding round

On May 1, 2018 Aegle Therapeutics completed their seed funding round with and undisclosed amount of funding from Ocean Azul Partners. 

People

Name
Role
LinkedIn

Evangelos Badiavas, M.D., PhD

Founder, CSO



Further reading

Title
Author
Link
Type
Date

2018 Drug Development Pipeline Review for Dermatological Burns, Scars and Ulcers - Features MediWound, Aegle Therapeutics, NovaLead Pharma, and many more

Research and Markets

Web



Aegle Therapeutics receives IND clearance from FDA for stem cell-derived extracellular vesicle therapy

Exosome RNA Administrator

Web



Florida Startups, Tech Investors Already Feel Sting of State Budget Cuts

Nancy Dahlberg

Web



Documentaries, videos and podcasts

Title
Date
Link

Aegle Therapeutics

October 18, 2019

Aegle Therapeutics hopes to treat rare pediatric skin disorder

January 10, 2019

Companies

Company
CEO
Location
Products/Services









References